Clinical Trial Update: TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins. [Phase 1]

View source ↗

Summary

Phase 1 study to assess whether TMC435 influences the activity of drug-degrading proteins by measuring blood levels of coadministered drugs degraded by those pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C, Viruses | Phase 1 | Status: COMPLETED